Noom Pivot to B2B2C Healthcare

This shows Noom is trying to turn weight loss from a one time consumer purchase into a reimbursed healthcare product. Selling through employers, insurers, and drug makers means Noom is no longer paid just for app subscriptions. It is paid for lowering claims, improving medication persistence, and giving large organizations a behavior change layer they do not build themselves.

• In practice, the buyer changes. Instead of convincing one consumer to pay $17 to $70 per month, Noom sells an employer, health plan, or pharma company a bundle of coaching, food logging, diabetes workflows, and GLP-1 support that can be rolled out to thousands or millions of covered lives at once.
  1 sacra 2 sacra 5 teladochealth
• The distribution advantage is real. Highmark said in October 2025 that it would make Noom available to nearly 2 million eligible members starting in 2026, and Castlight added Noom programs to its navigation platform in December 2025, giving benefits teams a pre integrated channel to buy weight, diabetes, and GLP-1 support together.
  1 sacra 3 highmarkhealth 4 hlth
• This also puts Noom into a different competitive set. Consumer app rivals like WeightWatchers matter less in enterprise sales than clinical workflow vendors like Omada and Vida, or telehealth programs like Teladoc that pair behavior support with medication access. The key question becomes which platform can keep patients engaged long enough to change outcomes and justify reimbursement.
  1 sacra 2 sacra 5 teladochealth

The next step is for Noom to become the default behavior layer around obesity treatment, especially GLP-1s. If more plans and pharma partners treat adherence and lifestyle coaching as part of the drug protocol, Noom can grow from a weight loss app into the software and support system that sits between the prescription, the payer, and the patient.